Company profile

Jazz Pharmaceuticals plc

NASDAQ:JAZZBiotechnology: Pharmaceutical Preparations

Drug pipeline (21)

AssetStageRevenueTrialsStatus
ASPARAGINASE ERWINIA CHRYSANTHEMIapproved2approved
CALCIUM OXYBATEapproved0
Cannabidiolapproved28approved
Clozapineapproved0
CYTARABINEapproved5approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (179)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02348632phase3completed2015-05-012017-12-01Jazz Pharmaceuticals"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
NCT02348619phase3completed2015-05-012016-11-01Jazz Pharmaceuticals"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
NCT02348593phase3completed2015-05-012017-02-01Jazz Pharmaceuticals"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
NCT02348606phase3completed2015-05-012016-12-01Jazz Pharmaceuticals"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
NCT03037203phase2completed2017-01-012018-08-01Jazz PharmaceuticalsA 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

FDA applications (12)

ApplicationTypeApplicantProducts
BLA 125359BLAJazz Pharmaceuticals, Inc.
BLA 761179BLAJazz Pharmaceuticals Ireland Limited
BLA 761416BLAJazz Pharmaceuticals Ireland Limited
NDA 021196NDAJAZZ PHARMACEUTICALS INC
NDA 021590NDAJAZZ PHARMACEUTICALS IRELAND LTD